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Des sources du savo ir aux méd icaments du F utur -From the sources of knowledge to the medieines of the Futu re
The example selected is the case of traditional remédies used for the treatment of malaria, and the objective is to prépare a médicinal product from a plant used in traditional medicine.
The work we report about is the resuit of scientific coopération bet¬ ween Faculté The approach we hâve adopted is ethnopharmacological; the aim was to prépare a médicinal product for émergent countries, i.e. a product reducing both parasitaemia and symptomatology, and featuring pharmaceutical qualifies while having a simple composition, so that production could be envisaged at a cost adapted to the mo¬ des! financial means that can be earmarked for health care.
Research work developed in 3 stages:
Inquiries : a total of three inquiries were conducted, in alternation with pharmacological and phytochemical studies. Pharmacological and phytochemical studies Designing a médicinal product following the recommendations of full market approval (FMA in abridged form), corresponding to the Cahier de l'Agence n°3, on a basis of a comprehensive pharma¬ ceutical assessment dossier and a short-term toxicological study. A second inquiry was conducted to confirm and complément the information collected about the traditional mode of préparation applied to Nouclea and Mi/ragyna. This second inquiry was carried out in 2 regional centres for trcd itionol medical practice in Kolokani and Sikasso. ln more thon half of the cases, the Mifragyno inermis leaves and the Nouclea lo/i(olio bark are associated and used as a macerat ion and -more frequently -a s a decoction. The product is generally absorbed per os or in a bath. The durat ion of the Ireatment is generally 2 to 7 doys according to the healers. Some of them recornmend not to use the aqueous decoction with pregnant women.
Inquiries
At the end of this second inquiry, we carr ied out a phytochemical and pharmocological sludy on these 2 species and on Glinus, and we could establish that the antiplasmodic action of Noucleo and Mi/ragyno is due to alkaloids and that of Glinus to saponos ides. A study of in vitro and in vivo mutagenes is carried out on the olkoloidal extract of Noucleo and Mi/rogyno, and on the saponic extract of Glinus permitted to establish that the alkaloids in Noucleo lo/i(olio have an in vitro and in vivo mutagenic action.
Moreover, in spite of the advantage offered by Glinus op positilolius, the low density of biotopes in Mali made it difficult, at the beginning, to develop an anti-malaria med icine from this plant. This is the reason why we decided to go on with our work using the leaves of Mifragyno inermis, whose alkaloids had shown, on the occasion of precedent research , that they have a choleretic action and do not have any hepatic toxicity.
M;tragyna inermis
The Mifragyno alkaloids are mainly composed of oxindoiic, tetraand pentacyclic derivatives. We isola ted ail the olkoloids. separot ed various fractions and isolated speciophylli n and iso-rhynchophylli n. We did not establish any significant difference in activity belween the isolated alkaloids, the alkaloidal fractions and the complete alkaloids. Therefore we went on with our experimentation on total olkoloids by setting up a dosage method permitting to evaluate ail the alkaloids in Ihe leaves, both in the tradilional preparations and in the extract that we had to prepare to be able to go on with the operation.
We recorded the quantity of plant used, the preparation mode, the pH of Au ids, the volume and quantity of samples, the durotion of the treatment and the set of symptoms presented by the palienls consulting the healer. The preparations were stored and the alkaloids were dosed. The solubil isation process of alkalo ids wa s ob served an d wa s assigned to either a highly acid pH, or to preparations requiring fermentation.
Development of a medicine following the abridged FMA procedure as described in Cahier de l'Agence no. 3.
First we prepared a pilot batch of hydro-alcoholic leaf extract enabling us to withdraw a mojority of wcter-soluble molecules and having an ethano/ic degree high enough to extract alkaloids.
Thi s extract wa s submitted to a pharmacological study to esta blish the cnti-plcsrnodic action, and a short term 28-days toxicological study with doses correspond ing to the posology that should be used in therapy and to 10 times the standard posology. The observat ion of the behaviour, the biological data and the anatomical and pathological study of various organs corried out after 28 days did not reveal any anomaly.
From there on, the ga lenic preparation of the finished product could be envisaged ; it was decided that it would be developed in the form of a tablet, which offers a better stability in a tropical environment. The pharmaceutical, pharmacological and toxicological dossiers will be submitted to the ethics committee in Bamako; the c1 inical studies to be conducted in 2 villages close to Bamako will then be carried out under the supervision of ProDoumbo in Bamako, Mali and Pro Delmont in Marseille, France. 
ALGERlA
HAURrTANIA
We then had to answer Iwo questions:
The first one was to determine whether the olkcloids which are unsolva ble in water in norma l conditions would dissolve in traditional preparations, and the second one was to measu re out the olkoloids in the preparations to set the posology to be used . This is why we initia ted a third inquiry that was carr ied out in Kolokani and Bandiagara, in the course of which we identified trcditional practitioners who used only Mitragyno inermis and who
